These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 10627383)

  • 1. Safety and efficacy of abciximab use in conjunction with intracoronary urokinase in patients requiring angioplasty.
    Rashdan I; Schechter E
    Catheter Cardiovasc Interv; 2000 Jan; 49(1):113-6. PubMed ID: 10627383
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Complications associated with combined use of abciximab and an intracoronary thrombolytic agent (urokinase or tissue-type plasminogen activator).
    Yaryura RA; Zaqqa M; Ferguson JJ
    Am J Cardiol; 1998 Aug; 82(4):518-9. PubMed ID: 9723644
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bleeding events with abciximab in acute coronary syndromes without early revascularization: An analysis of GUSTO IV-ACS.
    Lenderink T; Boersma E; Ruzyllo W; Widimsky P; Ohman EM; Armstrong PW; Wallentin L; Simoons ML;
    Am Heart J; 2004 May; 147(5):865-73. PubMed ID: 15131544
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Local intraarterial urokinase thrombolysis of acute ischemic stroke with or without intravenous abciximab: a pilot study.
    Lee DH; Jo KD; Kim HG; Choi SJ; Jung SM; Ryu DS; Park MS
    J Vasc Interv Radiol; 2002 Aug; 13(8):769-74. PubMed ID: 12171979
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Peripheral artery occlusion: treatment with abciximab plus urokinase versus with urokinase alone--a randomized pilot trial (the PROMPT Study). Platelet Receptor Antibodies in Order to Manage Peripheral Artery Thrombosis.
    Duda SH; Tepe G; Luz O; Ouriel K; Dietz K; Hahn U; Pereira P; Marsalek P; Ziemer G; Erley CM; Claussen CD
    Radiology; 2001 Dec; 221(3):689-96. PubMed ID: 11719664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bleeding risks with abciximab after full-dose thrombolysis in rescue or urgent angioplasty for acute myocardial infarction.
    Jong P; Cohen EA; Batchelor W; Lazzam C; Kreatsoulas C; Natarajan MK; Strauss BH
    Am Heart J; 2001 Feb; 141(2):218-25. PubMed ID: 11174335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Standard versus low-dose weight-adjusted heparin in patients treated with the platelet glycoprotein IIb/IIIa receptor antibody fragment abciximab (c7E3 Fab) during percutaneous coronary revascularization. PROLOG Investigators.
    Lincoff AM; Tcheng JE; Califf RM; Bass T; Popma JJ; Teirstein PS; Kleiman NS; Hattel LJ; Anderson HV; Ferguson JJ; Cabot CF; Anderson KM; Berdan LG; Musco MH; Weisman HF; Topol EJ
    Am J Cardiol; 1997 Feb; 79(3):286-91. PubMed ID: 9036746
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful dissolution of occlusive coronary thrombus with local administration of abciximab during PTCA.
    Bartorelli AL; Trabattoni D; Galli S; Grancini L; Cozzi S; Ravagnani P
    Catheter Cardiovasc Interv; 1999 Oct; 48(2):211-3. PubMed ID: 10506783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ClearWayRX system to reduce intracoronary thrombus in patients with acute coronary syndromes according to optical coherence tomography after abciximab intracoronary local infusion trial (COCTAIL): study rationale and design.
    Capodanno D; Prati F; Pawlowsky T; Ramazzotti V; Albertucci J; La Manna A; Robert G; Tamburino C
    J Cardiovasc Med (Hagerstown); 2010 Feb; 11(2):130-6. PubMed ID: 19829141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Does intracoronary abciximab improve the outcome of percutaneous coronary interventions? A randomized controlled trial].
    Galache Osuna JG; Sánchez-Rubio J; Calvo I; Diarte JA; Lukic A; Placer LJ
    Rev Esp Cardiol; 2006 Jun; 59(6):567-74. PubMed ID: 16790200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.
    van den Merkhof LF; Zijlstra F; Olsson H; Grip L; Veen G; Bär FW; van den Brand MJ; Simoons ML; Verheugt FW
    J Am Coll Cardiol; 1999 May; 33(6):1528-32. PubMed ID: 10334418
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized two-by-two comparison of high-dose bolus tirofiban versus abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary revascularization and stent placement: the tirofiban evaluation of novel dosing versus abciximab with clopidogrel and inhibition of thrombin (TENACITY) study trial.
    Moliterno DJ;
    Catheter Cardiovasc Interv; 2011 Jun; 77(7):1001-9. PubMed ID: 21598351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reduced thrombus burden with abciximab delivered locally before percutaneous intervention in saphenous vein grafts.
    Barsness GW; Buller C; Ohman EM; Schechter E; Pucillo A; Taylor MA; Miller MJ; Reiner JS; Churchill D; Chandler AB; Gonzalez M; Smith J; Tommaso C; Berdan LG; Wildermann NM; Hasdai D; Holmes DR
    Am Heart J; 2000 May; 139(5):824-9. PubMed ID: 10783216
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Benefits from intracoronary as compared to intravenous abciximab administration for STEMI patients undergoing primary angioplasty: a meta-analysis of 8 randomized trials.
    De Luca G; Verdoia M; Suryapranata H
    Atherosclerosis; 2012 Jun; 222(2):426-33. PubMed ID: 22483166
    [TBL] [Abstract][Full Text] [Related]  

  • 15. "Rescue" utilization of abciximab for the dissolution of coronary thrombus developing as a complication of coronary angioplasty.
    Muhlestein JB; Karagounis LA; Treehan S; Anderson JL
    J Am Coll Cardiol; 1997 Dec; 30(7):1729-34. PubMed ID: 9385900
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of intracoronary thrombus with local urokinase infusion using a new, site-specific drug delivery system: the Dispatch catheter.
    McKay RG; Fram DB; Hirst JA; Kiernan FJ; Primiano CA; Rinaldi MJ; Azrin MA; Mitchel JF; Waters DD
    Cathet Cardiovasc Diagn; 1994 Oct; 33(2):181-8. PubMed ID: 7834736
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of thrombocytopenia following coronary stent placement using abciximab plus clopidogrel or ticlopidine.
    Dillon WC; Eckert GJ; Dillon JC; Ritchie ME
    Catheter Cardiovasc Interv; 2000 Aug; 50(4):426-30. PubMed ID: 10931614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of abciximab during percutaneous coronary intervention reduces both ex vivo platelet thrombus formation and fibrin deposition: implications for a potential anticoagulant effect of abciximab.
    Dangas G; Badimon JJ; Coller BS; Fallon JT; Sharma SK; Hayes RM; Meraj P; Ambrose JA; Marmur JD
    Arterioscler Thromb Vasc Biol; 1998 Aug; 18(8):1342-9. PubMed ID: 9714143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abciximab readministration: A single-operator community-hospital experience.
    Arjomand H; Magsi ZM; Chang KS; Mascarenhas DA
    Catheter Cardiovasc Interv; 1999 Jul; 47(3):294-6; discussion 297. PubMed ID: 10402280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Abciximab as an adjunct to high-risk carotid or vertebrobasilar angioplasty: preliminary experience.
    Qureshi AI; Suri MF; Khan J; Fessler RD; Guterman LR; Hopkins LN
    Neurosurgery; 2000 Jun; 46(6):1316-24; discussion 1324-5. PubMed ID: 10834637
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.